Republican Congressman Tom Davis of Virginia, chair of the House Government Reform Committee, demanded answers from FDA acting commissioner Dr. Lester Crawford regarding drug safety protocols, Vioxx issues, and potential risks in similar medications.
Dr. Eric Topol criticized FDA for not investigating Vioxx heart problems earlier.
Concerns over Celebrex and other pain relievers' heart risks emerged.
FDA expert Dr. David Graham faced resistance over Vioxx safety findings.
Merck's withdrawal of Vioxx raised questions about FDA oversight.
The need for stricter drug testing and monitoring was emphasized.
The impact of drug advertising on consumer choices was also highlighted.
